Introduction: We investigated the efficacy and necessity of repeat transurethral resection (Re-TUR) in T1 bladder cancer. Patients and Methods: From September 2004 to September 2009, 62 patients with pathologically confirmed T1 bladder tumours were investigated. Re-TUR was routinely performed within 3–6 weeks following the initial resection. The pathological results of the Re-TUR were reviewed, and the risk of recurrence was investigated. Results: Of the 62 patients who underwent Re-TUR, 22 had a residual tumour pathologically. Visible residual tumours were detected in 9 patients (14.5%). The risk of having a residual tumour was directly correlated with the diameter of the initial tumour in T1 tumours (p = 0.007). Conclusions: Upstaging to T2 of the disease led to radical cystectomy in 11.29% of the patients in our series. Re-TUR should be routinely performed on all patients, especially on patients with high-grade tumours and with tumour diameters greater than 3 cm in T1 bladder cancer.

Keywords:
T1 bladder cancer, Repeat transurethral resection, Recurrence
This content is only available via PDF.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.